← Leaderboards
Stephany Yi Tzeng
Johns Hopkins University
$2,595,827
Attributed
$2,595,827
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $749.2K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,595,827 · 1
By mechanism
R37$2,595,827 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jordan Green$12,034,081
- Kam W Leong$23,208,213
- Drew M. Pardoll$27,059,898
- Robert H Gilman$35,342,766
- Peter C Searson$8,273,109
Others in their field
Other Emerging Leaders on “Conventional Therapy”
- Ionut Bebu · George Washington University$14,825,594
- Barbara Halina Braffett · George Washington University$14,825,594
- Barbara Burtness · Yale University$11,782,712
- Jessica Scott · Sloan-Kettering Inst Can Research$8,125,046
- Avnesh Sinh Thakor · Stanford University$6,735,528
- Scott F Lempka · University Of Michigan At Ann Arbor$4,851,845
Research focus
Conventional TherapyCytokineCoculture TechniquesComplexClinicCostAnti-CancerAnti-Tumor Immune ResponseAntitumor ResponseAntigen-Presenting CellsAntigensBiologicalClinical TranslationBlood Group Antigen SCancer CellCancer ImmunotherapyCancer ModelCd80 GeneCd8-Positive T-LymphocytesCell GrowthArtificial NanoparticlesCellsCellular ImmunotherapyCytotoxic T-Lymphocytes
Grant awards (6)
A Platform Technology to Genetically Reprogram Cancer Cells for Enhanced Immunotherapy$749,156
R37 · FY2025 · CA · contact PI
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY$355,850
R37 · FY2024 · CA · contact PI
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY$367,087
R37 · FY2023 · CA · contact PI
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY$374,578
R37 · FY2022 · CA · contact PI
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY$374,578
R37 · FY2021 · CA · contact PI
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY$374,578
R37 · FY2020 · CA · contact PI